We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA Updates Progress on Reforms in Response to Critical Findings

MHRA Updates Progress on Reforms in Response to Critical Findings

July 10, 2015

After receiving a less-than-favorable review on engagement with the clinical community, the UK’s Medicines and Healthcare products Regulatory Agency says it has made progress on this front — including forming an independent Devices Expert Advisory Committee and hiring clinical staff capable of peer-to-peer dialogue with healthcare leaders.

But, as the agency notes, challenges remain.

Published July 3, the MHRA report touches on 12 recommendations by Professor Terence Stephenson, chair of the General Medical Council, who led an independent team to assess the agency’s access to expert advice on devices, and found it lacking. The agency has identified the initial 14 stakeholder groups whose expertise would be needed for the DEAC, and a kickoff meeting is expected to take place this month.

The DEAC is expected to play a prominent role in helping the MHRA assume a more proactive role in building relationships and exchanging information with clinical groups within the UK. In fact, the agency already has contacted the Royal Colleges and specialist societies to help develop and manage a structured network of clinical advisers, rather than relying on an ad hoc group.

In terms of hiring clinical staff, the MHRA notes it has a full complement for the devices division — three medically trained positions and a senior nurse. In addition, the agency has developed a career pathways group to address recruitment and retention issues within the division.

However, recruitment, training and development of clinical staff remain critical challenges, the MHRA notes.

The report also touches on steps taken to support the safe introduction of innovative technologies in clinical practice, particularly in the wake of the Poly Implant Prothèse breast implant scandal (see related story). The agency says it has been active in a range of areas, including regenerative medicine and software as a medical device.

Still, work remains. “Current resource constraints severely limit our ability to provide more support and communication to companies, particularly considering the regulatory processes for novel devices and those that span the regulatory environments for both devices and pharmaceuticals, such as combination products and diagnostics supporting personalized medicine,” the agency says.

To read the full progress report, visit www.fdanews.com/07-13-15-MHRA-update.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Sanofi-logo.gif

    Sanofi’s Sarclisa Earns Second EC Clearance for Multiple Myeloma

  • emergency use authorization approved

    Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test

  • Withdraws cubes

    Zynteglo Gene Therapy Withdrawn in Germany

  • CE mark

    Empowered Diagnostics Earns CE Mark for Rapid COVID-19 Antigen Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing